Cargando…

Once-daily medications for the pharmacological management of ADHD in adults

Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed psychiatric disorder in children and adolescents. Symptoms of ADHD often persist beyond childhood and present significant challenges to adults. Pharmacotherapy is a first-line treatment option for ADHD across all age grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Tcheremissine, Oleg V, Lieving, Lori M
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697545/
https://www.ncbi.nlm.nih.gov/pubmed/19536322
_version_ 1782168339420807168
author Tcheremissine, Oleg V
Lieving, Lori M
author_facet Tcheremissine, Oleg V
Lieving, Lori M
author_sort Tcheremissine, Oleg V
collection PubMed
description Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed psychiatric disorder in children and adolescents. Symptoms of ADHD often persist beyond childhood and present significant challenges to adults. Pharmacotherapy is a first-line treatment option for ADHD across all age groups. The current review’s goals are (a) to critically examine the current state of knowledge regarding once-daily formulations of pharmacotherapies for treatment of adults with ADHD and (b) to provide clinicians with evidence-based information regarding the safety, efficacy and tolerability of once-daily medications for adult ADHD. The reviewed body of evidence strongly supports the use of pharmacotherapy as a first-line therapeutic option for the treatment of adults with ADHD. The once-daily pharmacological agents are effective therapeutic options for the treatment of adults with ADHD. In the US, based on the available evidence, once-daily medications are currently underutilized in adults with ADHD compared to pediatric population.
format Text
id pubmed-2697545
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26975452009-06-17 Once-daily medications for the pharmacological management of ADHD in adults Tcheremissine, Oleg V Lieving, Lori M Ther Clin Risk Manag Review Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed psychiatric disorder in children and adolescents. Symptoms of ADHD often persist beyond childhood and present significant challenges to adults. Pharmacotherapy is a first-line treatment option for ADHD across all age groups. The current review’s goals are (a) to critically examine the current state of knowledge regarding once-daily formulations of pharmacotherapies for treatment of adults with ADHD and (b) to provide clinicians with evidence-based information regarding the safety, efficacy and tolerability of once-daily medications for adult ADHD. The reviewed body of evidence strongly supports the use of pharmacotherapy as a first-line therapeutic option for the treatment of adults with ADHD. The once-daily pharmacological agents are effective therapeutic options for the treatment of adults with ADHD. In the US, based on the available evidence, once-daily medications are currently underutilized in adults with ADHD compared to pediatric population. Dove Medical Press 2009 2009-05-20 /pmc/articles/PMC2697545/ /pubmed/19536322 Text en © 2009 Tcheremissine and Lieving, publisher and licensee Dove Medical Press Ltd.
spellingShingle Review
Tcheremissine, Oleg V
Lieving, Lori M
Once-daily medications for the pharmacological management of ADHD in adults
title Once-daily medications for the pharmacological management of ADHD in adults
title_full Once-daily medications for the pharmacological management of ADHD in adults
title_fullStr Once-daily medications for the pharmacological management of ADHD in adults
title_full_unstemmed Once-daily medications for the pharmacological management of ADHD in adults
title_short Once-daily medications for the pharmacological management of ADHD in adults
title_sort once-daily medications for the pharmacological management of adhd in adults
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697545/
https://www.ncbi.nlm.nih.gov/pubmed/19536322
work_keys_str_mv AT tcheremissineolegv oncedailymedicationsforthepharmacologicalmanagementofadhdinadults
AT lievinglorim oncedailymedicationsforthepharmacologicalmanagementofadhdinadults